Telix Pharmaceuticals Limited (TLX)
TLXNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$9.15
-0.2900 (-3.07%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $3.13bn
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $6.28 to $13.11
- Average volume
- –
- Previous close
- $9.44
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $20.00, +118.6% from here
Earnings
next estimate $-0.0200Next report
Financials
| Quarter | Mar 2024 | Jun 2024 |
|---|---|---|
| Revenue | $114.17m | $128.90m |
| Gross profit | $75.26m | $84.37m |
| Operating income | $18.60m | $9.44m |
| Net income | $11.73m | $8.08m |
News
8 latest- Telix Targets $1.5 Bln Revenue In 2027 As ITM Deal May Accelerate Therapy Launch To 2027 RTTNews · Nov 5, 2026
- Telix Pharmaceuticals Targets $1.5B Revenue as ITM Deal Speeds Therapy PushMarketBeat · Nov 4, 2026
- Weekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win RTTNews · Oct 23, 2026
- Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance And Advances Pipeline Programs RTTNews · Oct 20, 2026
- Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance RTTNews · Oct 20, 2026
- GE HealthCare Wins Approval for MINItrace Magni Cyclotron in EuropeZacks · Oct 20, 2026
- FDA Drug Approvals In September 2026 RTTNews · Oct 16, 2026
- Profound Medical, Telix Pharma Sign Co-Education Deal To Advance PSMA-Informed Prostate Care RTTNews · Oct 9, 2026
The company
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. Telix's commercial franchise is anchored by its precision diagnostics portfolio: Illuccix (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S., Gozellix (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. FDA, and Pixclara (floretyrosine F 18) approved by the FDA for glioma imaging.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- Australia and South Pacific
- Website
- telixpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.